Work

Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib

Year: 2010

Type: article

Abstract: The overall survival for patients with advanced hepatocellular carcinoma (HCC) is still limited. Although the multi-kinase inhibitor sorafenib has recently been approved for this disease, response rates are still low and patients often face dose-limiting toxicities which lead to a reduction in prognosis and treatment success. We here report a patient with metastasized HCC who shows a sustained response for more than 30 mo to sorafenib therapy after failure of a first line therapy with gemcitabine, oxaliplatin and bevacizumab.

Source: World Journal of Gastroenterology

DOI: 10.3748/wjg.v16.i28.3592

Author: Christina Wich

Institution: Universitätsklinikum Erlangen

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W2111038776

FWCI: 1.302

Cites: 30

Cited by: 8

Related to: 10